These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27832416)

  • 21. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
    Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D
    Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of cerebellar pathology in the canine model of mucopolysaccharidosis type IIIA (MPS IIIA).
    Hassiotis S; Jolly RD; Hemsley KM
    Mol Genet Metab; 2014 Dec; 113(4):283-93. PubMed ID: 25453402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA.
    King B; Savas P; Fuller M; Hopwood J; Hemsley K
    Mol Genet Metab; 2006 Feb; 87(2):107-12. PubMed ID: 16352454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases.
    Hemsley KM; Hopwood JJ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S118-23. PubMed ID: 20040322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel treatments and future perspectives: outcomes of intrathecal drug delivery.
    Dickson PI
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S124-7. PubMed ID: 20040323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA.
    Makower Å; Arnelöf E; Andersson T; Edlund PO; Gustavsson S; Janson J; Gelius SS; Tjernberg A
    Bioanalysis; 2019 Aug; 11(15):1389-1403. PubMed ID: 31490106
    [No Abstract]   [Full Text] [Related]  

  • 27. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA.
    Savas PS; Hemsley KM; Hopwood JJ
    Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
    Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
    J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
    Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
    Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice.
    Dwyer CA; Scudder SL; Lin Y; Dozier LE; Phan D; Allen NJ; Patrick GN; Esko JD
    Sci Rep; 2017 Apr; 7():46576. PubMed ID: 28418018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice.
    Kaidonis X; Byers S; Ranieri E; Sharp P; Fletcher J; Derrick-Roberts A
    Mol Genet Metab; 2016 Jun; 118(2):100-10. PubMed ID: 27106513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse.
    Paget TL; Parkinson-Lawrence EJ; Trim PJ; Autilio C; Panchal MH; Koster G; Echaide M; Snel MF; Postle AD; Morrison JL; Pérez-Gil J; Orgeig S
    Cells; 2021 Apr; 10(4):. PubMed ID: 33918094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design.
    Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM
    Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
    Jones SA; Breen C; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Pan L; Qiu Y; Chung JK; Nair N; Haslett PAJ; Barbier AJ; Wijburg FA
    Mol Genet Metab; 2016 Jul; 118(3):198-205. PubMed ID: 27211612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central nervous system pathology in preclinical MPS IIIB dogs reveals progressive changes in clinically relevant brain regions.
    Egeland MT; Tarczyluk-Wells MM; Asmar MM; Adintori EG; Lawrence R; Snella EM; Jens JK; Crawford BE; Wait JCM; McCullagh E; Pinkstaff J; Cooper JD; Ellinwood NM
    Sci Rep; 2020 Nov; 10(1):20365. PubMed ID: 33230178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study.
    Harmatz P; Muenzer J; Ezgü F; Dalén P; Huledal G; Lindqvist D; Gelius SS; Wikén M; Önnestam K; Bröijersén A
    Mol Genet Metab; 2022 Aug; 136(4):249-259. PubMed ID: 35835061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.
    Downs-Kelly E; Jones MZ; Alroy J; Cavanagh KT; King B; Lucas RE; Baker JC; Kraemer SA; Hopwood JJ
    J Mol Neurosci; 2000 Dec; 15(3):251-62. PubMed ID: 11303788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.